View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Palomar Holdings, Inc. Announces Agreement to Acquire The Gray Casualt...

Palomar Holdings, Inc. Announces Agreement to Acquire The Gray Casualty & Surety Company Builds Scale in the Attractive Surety Market LA JOLLA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Palomar Holdings, Inc. (NASDAQ: PLMR) (“Palomar”, the “Company”) today announced that it has entered into a definitive agreement to acquire The Gray Casualty & Surety Company (“Gray Surety”) from Bernhard Capital Partners (“BCP”) and The Gray Insurance Company for total consideration of $300 million in cash subject to customary closing adjustments. The transaction has been approved by both Gray Surety an...

 PRESS RELEASE

Palomar Holdings, Inc. Announces Third Quarter 2025 Financial Results ...

Palomar Holdings, Inc. Announces Third Quarter 2025 Financial Results Release Date and Conference Call LA JOLLA, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Palomar Holdings, Inc. (NASDAQ: PLMR) (the “Company”) today announced that it will release its third quarter 2025 results after market close on Thursday, November 6, 2025, and will host a conference call at 12:00 p.m. (Eastern Time) the following day, Friday, November 7, 2025. The conference call can be accessed live by dialing 1-877-423-9813 or for international callers, 1-201-689-8573, and requesting to be joined to the Palomar Third...

 PRESS RELEASE

Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results ...

Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 BOSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 4, 2025 to report its third quarter 2025 financial results and provide a corporate update. To access the live conference call, participants may register . While n...

 PRESS RELEASE

ARRAY Technologies, Inc. Announces Third Quarter 2025 Earnings Release...

ARRAY Technologies, Inc. Announces Third Quarter 2025 Earnings Release Date and Conference Call ALBUQUERQUE, N.M., Oct. 16, 2025 (GLOBE NEWSWIRE) -- ARRAY Technologies, Inc. (the “Company” or “ARRAY”) (NASDAQ: ARRY), a leading global provider of solar tracking technology and fixed-tilt system products, software, services and foundation solutions, today announced that the Company will release its third quarter 2025 results after the market closes on Wednesday, November 5, 2025, to be followed by a conference call at 5:00 p.m. (Eastern Time) that same day. The conference call can be access...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

BKD BROOKDALE SENIOR LIVING INC.
XENE XENON PHARMACEUTICALS INC
SEDG SOLAREDGE TECHNOLOGIES INC.
RUN SUNRUN INC.
LTRX LANTRONIX INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
LAKE LAKELAND INDUSTRIES INC.
CEVA CEVA INC.
ASPS ALTISOURCE PORTFOLIO SOLUTIONS S.A.
ALB ALBEMARLE CORPORATION
EFR ENERGY FUELS
RELL RICHARDSON ELECTRONICS LTD.
NTLA INTELLIA THERAPEUTICS INC.
UAMY UNITED STATES ANTIMONY CORP.
BOMN BOSTON OMAHA
ICL ICL GROUP LTD.
LWLG LIGHTWAVE LOGIC
IMTX IMMATICS N V (A)
ARRY ARRAY TECHNOLOGIES
IMVT IMMUNOVANT
RLAY RELAY THERAPEUTICS
FLUX FLUX POWER HOLDINGS
GLUE MONTE ROSA THERAPEUTICS INC
ASTS AST SPACEMOBILE INC
TRDA ENTRADA THERAPEUTICS INC
JANX JANUX THERAPEUTICS INC
APLD APPLIED BLOCKCHAIN INC
IE IVANHOE ELECTRIC INC
NUVL NUVALENT INC
COHR COHERENT CORP
CRML CLAL INDUSTRIES & BEVERAGES LTD
GPCR STRUCTURE THERAPEUTICS
OCS OCULIS HOLDING AG
LAES SEALSQ CORP
NB NIOCORP DEVELOPMENTS LTD.
METBV FORTREA HOLDINGS INC.
FTREV SAGIMET BIOSCIENCES INC
SGMT BYRNA TECHNOLOGIES INC
BYRN ENGENE HOLDINGS INC
ENGN SPYRE THERAPEUTICS INC.
SYRE NEUROGENE INC
NGNE RAMACO RESOURCES INC.
METC TOYO CO LTD
TOYO SERVE ROBOTICS INC
SERV UPSTREAM BIO INC
UPB CIDARA THERAPEUTICS INC.
CDTX AMERICAN BATTERY TECHNOLOGY COMPANY
ABAT TVARDI THERAPEUTICS INC
TVRD USA RARE EARTH INC
USAR HYCROFT MINING HOLDING CORPORATION
HYMC CATALYST PERINI STRATEGIC INCOM ORD
CSIOX CHARGEPOINT HOLDINGS INC.
CHPT KULR TECHNOLOGY GROUP INC.
KULR GRAFTECH INTERNATIONAL LTD.
EAF GLOBALSTAR INC.
GSAT INHIBRX BIOSCIENCES INC.
INBX KON TUM CONSTRUCTION MATERIALS ORD
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Wedbush Research
  • Wedbush Research

Geo Group Inc: 1 director

A director at Geo Group Inc sold 93,528 shares at 20.850USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

 PRESS RELEASE

ARRAY Technologies Confirms Compatibility with 2000-Volt Solar Project...

ARRAY Technologies Confirms Compatibility with 2000-Volt Solar Projects Technical evaluation verifies DuraTrack® and OmniTrack™ systems meet industry standards for next-generation solar installations ALBUQUERQUE, N.M., Sept. 03, 2025 (GLOBE NEWSWIRE) -- ARRAY Technologies (NASDAQ: ARRY) (“ARRAY” or the “Company”), a leading global provider of solar tracking technology products, software, services and foundation solutions, announced today that its DuraTrack® and OmniTrack™ systems have been verified by Intertek to be compatible with 2000-volt (2kV) module-wired systems. This milestone re...

 PRESS RELEASE

Palomar Holdings, Inc. Announces Participation in the 2025 KBW Insuran...

Palomar Holdings, Inc. Announces Participation in the 2025 KBW Insurance Conference LA JOLLA, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Palomar Holdings, Inc. (NASDAQ: PLMR) (“Palomar”) today announced that Mac Armstrong, Chairman and Chief Executive Officer, and Chris Uchida, Chief Financial Officer, will participate in a fireside chat at the KBW Insurance Conference on Thursday, September 4, 2025 at 10:35 am ET. Management will also be available for one-on-one and small group meetings with investors. Interested investors and other parties can access a live webcast of the presentation b...

 PRESS RELEASE

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Co...

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in fireside chats at two upcoming investor conferences: Wells Fargo Healthcare Conference on Wednesday, September 3, 2025 at 9:30 a.m. ETMorgan Stanley Global Healthcare Conference on...

 PRESS RELEASE

Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanot...

Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity – U.S. Food and Drug Administration accepts sNDA for filing with priority review; sets PDUFA goal date of December 20, 2025 -- – European Medicines Agency accepts and validates submission for Type II variation MAA for setmelanotide to treat acquired hypothalamic obesity – – Company to host “Commercial Readiness for Acquired Hypothalamic Obesity,” event for investors and analysts on Wednesday, September 24, in Boston – BOSTON, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceutical...

 PRESS RELEASE

ARRAY Technologies Completes Acquisition of APA Solar

ARRAY Technologies Completes Acquisition of APA Solar Combined product portfolio positions ARRAY to deliver fully integrated tracker and engineered foundation solutions for the solar industry ALBUQUERQUE, N.M., Aug. 14, 2025 (GLOBE NEWSWIRE) -- ARRAY Technologies (NASDAQ: ARRY) (“ARRAY” or the “Company”), a leading global provider of solar tracking technology products, software, and services for utility-scale solar energy projects, today announced the successful completion of its acquisition of APA Solar (“APA”), a premier solar racking and structural solutions provider. This strategic ...

 PRESS RELEASE

ARRAY Technologies, Inc. to Participate in Upcoming Investor Conferenc...

ARRAY Technologies, Inc. to Participate in Upcoming Investor Conferences and Events ALBUQUERQUE, N.M., Aug. 12, 2025 (GLOBE NEWSWIRE) -- ARRAY Technologies (NASDAQ: ARRY) (“ARRAY” or the “Company”), a leading global provider of solar tracking technology products, software and services, today announced its attendance at the following upcoming investor events: Citi’s 2025 Natural Resources Conference August 14, 2025 in Las VegasARRAY’s CFO, H. Keith Jennings, will host in-person investor meetings. Interested investors should contact their Citi sales representative. Barclays 39th Annual En...

 PRESS RELEASE

ARRAY Technologies, Inc. Reports Financial Results for the Second Quar...

ARRAY Technologies, Inc. Reports Financial Results for the Second Quarter 2025 Commercial excellence continues to deliver, year-to-date volume growth up 84% over 2024 2025 Second Quarter Highlights Revenue of $362.2 millionGross Margin of 26.8%Adjusted gross margin(1) of 27.8%Net income to common shareholders of $28.5 millionAdjusted EBITDA(1) of $63.6 millionNet income per basic and diluted share of $0.19Adjusted net income per diluted share(1) of $0.25Total executed contracts and awarded orders at June 30, 2025 were over $1.8 billion Inclusive of strategic descoping and reconfigu...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch